How 18-MC is targeting the root causes of addictive behaviour

Episode Loading...

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How 18-MC is targeting the root causes of addictive behaviour
Released on: November 20, 2015. © PharmaVentures Ltd
Share/save this page:
Follow us:
In This Episode:
    Savant HWP, Inc.
  • Summary
  • Transcript
  • Participants
  • Company
Savant HWP, Inc., is a privately held company focused on the area of substance addiction. Unlike traditional substitution and aversion therapies, Savant’s lead compound, 18-MC, aims to address the root causes of addictive behaviour by uniquely targeting the dysregulation of dopamine in the brain. Steve Hurst, CEO and founder of Savant HWP, talks to Fintan Walton about the science behind 18-MC, and current plans for efficacy testing in an array of substance addictions including cocaine, opiates, methamphetamine, nicotine and alcohol.
In 2013, an estimated 22.7 million Americans (8.6 percent) needed treatment for a problem related to drugs or alcohol, but only about 2.5 million people (0.9 percent) received treatment at a specialty facility. The total social and health cost to American society of dealing with alcohol and illegal drug abuse is estimated to exceed $167 billion annually. Steve Hurst, CEO of Savant HWP explains to Fintan Walton, CEO of PharmaVentures, how they are taking a different approach to tackling addiction with their Addiction Medicine 18-MC.
Steve Hurst. Founder, Director. President and CEO. Mr. Hurst has more than twenty-five years experience in the biopharmaceutical industry and has contributed to the success of numerous complex and challenging healthcare projects. As the Chief Business Officer for The Immune Tolerance Institute (2007-2011), he helped establish a human immune monitoring institute for The Regents of the University of California that discovers and develops immune biomarkers. As a consultant to The World Bank and BIO Ventures for Global Health (2005-2009), he helped establish an innovative funding mechanism for pneumococcal vaccines for the developing world (PneumoAMC), including capacity for two billion vaccine doses and funding of more than $4 billion over the next decade. As Founder, President & CEO of Sequential, Inc. (2002-2004), his team acquired and developed a clinical-stage oncology drug for the treatment of multi-drug resistance. While at Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.) (1994-2002), he held several senior executive positions, including Executive Vice President, General Counsel and Secretary, interim Senior Vice President of Operations, Vice President of Intellectual Property and Licensing and Head of Business Development and helped the company grow to over 700 employees, raise more than $700 million in investment capital and out-license multiple clinical development projects, generating revenues in excess of $100 million annually. Mr. Hurst is a graduate of Golden Gate University, School of Law and the University of California, Berkeley.
Savant HWP
Savant HWP was founded in 2009 to create transformational products in human health, wellness and prevention. Our first products address unmet needs in addiction medicine, where current products are largely ineffective. Addiction results from powerful neurochemical changes in the pleasure centers of the brain. Changes that are not subject to willpower. Addiction is not limited to drugs, alcohol and nicotine. Even food can be just as harmful and, in some ways, more challenging. Addiction affects all of us and our daily lives. Curing addiction requires transformational products that reverse these neurochemical changes, freeing the patient from the uncontrollable desire for the addictive substance or compulsive pleasure-seeking behavior. Current approaches in addiction medicine do not accomplish this. As Savant HWP grows, so will our product offerings with an eye to maximizing patient benefits and value to the people who stand behind the name.